Coronado Industries PNT Treatment Featured at Equities Magazine Investors Conference in New York; Investors Told of the Advances Made by the Company by Non-Invasive Treatment for Glaucoma.

FOUNTAIN HILLS, Ariz. -- Dr. John Sharkey, president of Ophthalmic International (www.ophthalmicinternational.com), the wholly owned subsidiary of Coronado Industries (OTCBB: CNDO) (www.coronadoindustries.com), was in New York on Friday, June 16, to address the Equities Magazine Investor Conference. Leading investors, institutions and financial advisors gathered at the Yale Club in New York to hear presentations made by senior management of a select group of promising technology companies.

A live webcast of Coronado's presentation can be accessed by visiting the Equities Magazine Web site at www.equitiesmagazine.com. Viewing is free and visitors need only to follow the on-screen instructions. The webcast will be archived for the next 90 days.

The opportunity to talk to this large group of investors came at a particularly eventful time for Coronado Industries. Investors were told of the multiple advantages of the company's non-invasive treatment for glaucoma, and the progress being made in various markets around the world. The company continues to make in-roads into major markets in Europe, where the product is already approved, having recently announced the execution of a new sales, marketing and distribution agreement covering France. He also shared that the company has initiated activities to accelerate the introduction of PNT into select African and South American countries, where the lack of available glaucoma treatments is having a devastating impact on patients and the economy.

Sharkey explained to the assembled investors that PNT lends itself perfectly to many areas of the world where access to pharmaceutical and surgical treatments are limited. As an example, in the west of Africa, where the incidence of glaucoma has been estimated to be approximately 20% in people over the age of 30 years, it is not uncommon to see people in their 40s and 50s blinded by the disease. The reasons for the poor availability of effective treatment is often driven by cultural, economic and logistical reasons, and include the high costs of pharmaceuticals and the lack of skilled ophthalmic surgeons required to perform the surgery. PNT has the advantages of being completely portable and relatively inexpensive to administer when compared to other treatments for glaucoma. It was, he said, an ideal solution for many nations whose governments and private medical services were burdened with the ever-growing problem of glaucoma, an incurable eye disease that affects millions of people, and which the World Health Organization has identified as the second-leading cause of preventable blindness worldwide. A vast majority of glaucoma sufferers are presently unable to access or afford effective treatment.

Sharkey said that given the number of distribution agreements the company has already signed, those that it is likely to sign in the near future, and the company's initiatives, some of which are already underway to introduce the product within Africa and South America, he believes that the company is making good progress. As the company moved forward with its strategy of making PNT available to a wider international patient population suffering from this devastating disease, he said he looked forward to sharing news of the company's achievements to more discerning investors in the coming months.

Equities Magazine, which has been published for more than 50 years, and covers small to mid cap companies, is widely read throughout the United States by individual and institutional investors, fund managers and financial advisors. It is soon to launch a European edition out of London.

Meanwhile, a corporate profile of Coronado, covering two pages, has been published in the June edition of the magazine, and will also appear in the new European edition, providing more exposure for Coronado and its PNT technology among investors in the United Kingdom and European financial markets.

Coronado Industries, through its wholly owned subsidiary Ophthalmic International, is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma, which are open angle and pigmentary, as well as for the treatment of ocular hypertension.

For more information about Coronado Industries, please visit our Web site at www.coronadoindustries.com or contact:

Bob Smith, Investor Relations         Victor Webb/Madlene Olson, Media
Coronado Industries                   Marston Webb International
480-837-6810                          212-684-6601

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.